SHP2 Inhibitor Signal pathway: RAS、I/OView More

 

JAB-3068 is theF second SHP2 inhibitor approved by the FDA to enter clinical development. JAB-3312, the second generation SHP2 inhibitor designed by Jacobio has more potent anti-tumor activities. Both compounds have been granted orphan drug designation by the FDA for the treatment of esophageal cancer (including esophageal squamous cell carcinoma).

As date of June 30, 2022
  • U.S.
  • China
  • Global

JAB-3312


Therapy Indications IND Phase I Phase II Recent progress

Monotherapy

Solid Tumor

 
 
 
 
Monotherapy

Solid Tumor

 
 
 
First patient in Phase IIa was enrolled
Jan, 2022
Monotherapy

Class 3 BRAF / NF1 LOF mutant solid tumor

 
 
 
First patient in Phase IIa was enrolled
Dec, 2021
PD-1 mAb Combination Therapy ESCC, HNSCC, NSCLC
 
 
 
Phase IIa initiated
Feb, 2022
MEKi Combination Therapy

KRAS mutation CRC, pancreatic cancer

 
 
 
 
KRAS G12Ci Combination Therapy KRAS G12C mutation NSCLC
 
 
 
First patient enrolled
Jan, 2022
EGFRi Combination Therapy

Osimertinib resistant NSCLC

 
 
 
First patient enrolled
Jan, 2022

 

JAB-3068

Therapy Indications IND Phase I Phase II Recent progress
Monotherapy Solid Tumor
 
 
 
 
Monotherapy ESCC, HNSCC, NSCLC
 
 
 
 
PD-1 mAb Combination Therapy ESCC, HNSCC, NSCLC
 
 
 
 

KRAS G12C Inhibitor Signal pathway: RASView More

JAB-21822

JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. From the in-house preclinical head-to-head study, this compound has superior oral bioavailability and systemic drug exposure, better pharmacokinetic profiles and tolerance, and is a potential best-in-class compound.

As date of June 30, 2022
  • U.S.
  • China
  • Global

JAB-21822

Therapy Indications IND Phase I Phase IIa Recent progress

Monotherapy

NSCLC, CRC

 
 
 
First patient enrolled
Sept, 2021
Monotherapy

NSCLC, CRC and other solid tumors

 
 
 
Registratinal trial to be initiated
Sept, 2022
Monotherapy NSCLC KRAS G12C co-mutated with STK11
 
 
 
IND approved
Oct, 2021
PD-1 mAb combination therapy NSCLC
 
 
 
IND approved
Oct, 2021

SHP2i combination therapy

NSCLC, CRC
 
 
 
First patient enrolled
May, 2022
EGFR mAb combination therapy CRC
 
 
 
Phase IIa initiated
June, 2022

BET Inhibitor Signal pathway: MYC View More

JAB-8263

JAB-8263 class 1 innovative drug that is a Bromodomain and Extra-Terminal motif (BET) inhibitor independently developed by Jacobio. Preclinical studies have shown that JAB-8263 can effectively inhibit tumor growth at very low concentrations. In addition to solid tumors, hematological tumors are particularly sensitive to JAB-8263. Patients with hematological tumors and some types of solid tumors may benefit from the treatment of JAB-8263.

As date of March 31, 2022
  • U.S.
  • China
  • Global

JAB-8263

Therapy Indications IND Phase I Phase II Recent progress

Monotherapy

Solid Tumor

 
 
 
 
Monotherapy

Solid Tumor

 
 
 
First patient enrolled
Feb, 2022
Monotherapy

MF, AML

 
 
 
First patient enrolled
Apr, 2021

Aurora A inhibitor Signal pathway: RBView More

JAB-2485

JAB-2485 is an Aurora Kinase A (AURKA) inhibitor developed independently by Jacobio Pharma. It inhibits AURKA effectively and does not affect the activity of other kinases structurally similar to AURKA, minimizing the toxicity of the drug and improving the therapeutic window.

As date of March 31, 2022
  • U.S.
  • China
  • Global

JAB-2485

Therapy Indications IND Phase I Phase II Recent progress

Monotherapy

Solid Tumor

 
 
 
IND Approved
Jan, 2022

CD73 monoclonal antibody Signal pathway: I/OView More

JAB-BX102

JAB-BX102 is a humanized anti-CD73 monoclonal antibody (mAb)developed by Jacobio to inhibit the enzymatic activity of CD73. CD73 is the key node of adenosine pathway, and its inhibitors have broad therapeutic prospects for tumors dependent on adenosine pathway. Relevant studies have shown that adenosine promotes SHP2 phosphorylation, suggesting that anti-CD73 antibody can be combined with SHP2 inhibitor, which is also developed by Jacobio to benefit patients with advanced solid tumors.

As date of March 31, 2022
  • U.S.
  • China
  • Global

JAB-BX102

Therapy Indications IND Phase I Phase IIa Recent progress

Mono and Combo w/ PD-1 antibody

Solid Tumor

 
 
 
IND approved in US
Oct, 2021

IND-enabling Stage Candidates

 

  Asset Target Lead Optimization Candidate IND-enabling IND Schedule Indications Recent Development
IND-Enabling
JAB-24114 Undisclosed
(Tumor metabolic pathway)
 
 
2022 2H NSCLC, HNSCC Candidate nominated, entering into IND-enabling studies in Mar 2021
JAB-BX300 Undisclosed
(RAS pathway)
 
 
2022 2H PDAC, CRC Candidate nominated, entering into IND-enabling studies in Mar 2021
JAB-26766 Undisclosed
(I/O)
 
 
2022-2023 SCLC, HNSCC, ESCC Candidate nominated, entering into IND-enabling studies in Mar 2021
JAB-23400 KRASmulti
(RAS pathway)
 
 
2023 PDAC, CRC, NSCLC Candidate nominated, entering into IND-enabling studies in Mar 2021
Lead Optimization
JAB-22000 KRAS G12D
(RAS pathway)
 
 
2023 PDAC, CRC, NSCLC Lead series identified and patent filed in Nov 2020
JAB-30000 P53
(P53 pathway)
 
 
2023-2024 Solid tumor Lead series identified and patent filed in 2021

Abbreviation: mAb = monoclonal antibody; ESCC = esophageal squamous cell carcinoma; HNSCC = head and neck squamous cell carcinoma; NSCLC = non CLC; KRAS amp = KRAS amplification; Lof = missing function; CRC = colorectal cancer; MF = bone marrow fibrosis; AML = acute myeloid leukemia; CRPC = castration resistant prostate cancer; HCC = hepatocellular carcinoma; PDAC = pancreatic ductal adenocarcinoma; Ind = new drug for clinical research or new drug application for clinical research.

As date of March 31, 2022